June 27, 2026 03:54 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Ram Mandir Trust chief Champat Rai resigns as alleged donation siphoning row escalates | Ram Mandir fund row deepens: 8 arrested days after BJP called allegations 'false narrative' | 'Who tied the hands of CBI?': Calcutta HC on RG Kar case; victim's mother, now BJP MLA, says she is 'deeply disturbed' | Construction comes to a standstill at nearly 700 Kolkata projects after Taratala warehouse tragedy kills 15 | World Cup shocker! Ecuador stun Germany 2-1, storm into Round of 32 | Iran-US conflict: Cargo vessel hit near Strait of Hormuz, UN agency pauses evacuation operations | Amazon's massive India bet! Andy Jassy announces $48 billion investment after meeting PM Modi | Taratala warehouse collapse: Death toll climbs to 8, five arrested as SIT launches probe | Oil prices crash, IndiGo takes off! Aviation and fuel stocks emerge as biggest winners | Passport is a travel document, not conclusive proof of citizenship: MEA
CoronaVac
Image: Pixabay

China's CoronaVac may be ineffective against Brazil COVID-19 variant: Study

| @indiablooms | Mar 13, 2021, at 04:34 pm

Sao Paulo: China’s CoronaVac might not be effective against the Brazilian COVID-19 strain, a study said.

The small-scale study, which is yet to be peer-reviewed, comes as doctors warn of a humanitarian catastrophe in Brazil over coming weeks, with surging deaths as the disease overwhelms hospitals across the country, The Wall Street Journal reported.

Researchers from Brazil, the U.K., and the U.S., found that plasma from eight people vaccinated five months ago with CoronaVac “failed to efficiently neutralize” the new Amazonian strain, called P.1.

The study didn’t show if CoronaVac can still stop people getting sick from the variant, one of the main goals of vaccination campaigns, the newspaper reported.

While the study’s sample size was small and requires further testing, the fact that all eight samples produced the same result is a “notable phenomenon,” suggesting CoronaVac is less capable of thwarting infections of P.1 than of versions of the virus previously found in Brazil, said William de Souza, of the University of São Paulo in Ribeirão Prêto, one of the study’s authors, the newspaper reported.

Sinovac, the Chinese firm that produces CoronaVac, however refused to comment on the issue to the newspaper.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.